Previously we showed that mildronate effectively protected mice heart tissue against the toxic influence of anti-HIV drugs azidothymidine, stavudine and lamivudine, which belong to nucleosideanalogue reverse transcriptase inhibitor (NRTI) 
INTRODUCTION
Our previous pharmacological studies have shown that mildronate, a well-known cardioprotective drug, has an ability to protect tissues from toxic influence of anti-HIV drugs that belong to nucleoside-analogue reverse transcriptase inhibitor (NRTI) class, such as azidothymidine, stavudine and lamivudine (Klusa et al., 2006; Isajevs et al., 2007) . Their side effects mostly are caused via deteriorating influence on mitochondrial processes (White, 2001) , however, organtoxicity depends on the drug used. For example, azidothymidine is characterised by its strong cardiotoxic effects, which is documented either in experiments or clinical studies (Peters et al., 1992; Corcuera Pindado et al., 1994; Szabados et al., 1999) , while stavudine therapy can induce hepatic steatosis and lactic acidosis (Miller et al., 2000) , which is less expressed for lamivudine (Caron et al., 2008) .
In the present study, we designed experiments to evaluate the influence of mildronate on indinavir-and efavirenz-induced toxic effects in mice cardiac tissue; additionally, efavirenz toxicity was also assessed in mice liver and brain tissues. Immunohistochemical studies were focused on transcription factor -nuclear factor kBp65 (NFkBp65), as well as active caspase-3, and glial fibrillary acidic protein (GFAP). NF-kB is involved in inflammatory responses by stimulating the production of proinflammatory cytokines, including interleukins (IL-1 and IL-6), inducible cyclooxygenase, and inducible nitric oxide synthase (Rahman and MacNee, 2000) . Therefore, cellular activation and an increase in inflammatory mediator synthesis indicate that NF-kB is activated (Di Stefano et al., 2002) . Caspase-3 is a central key enzyme in many cells, leading to DNase activation, followed by DNA fragmentation (Enari et al., 1998) . In normal cells, caspase-3 exists as a procaspase in which the potential cleavage site is intact. Once cleaved through the activation of the apoptotic cascade, the peptide end of this active caspase represents a novel epitope which is not presented in normal cells. Therefore, the detection of this novel epitope is a unique and sensitive indicator of apoptosis (Gown and Willingham, 2002) . GFAP is a significant structural protein of glial astrocytes, which provide neuronal-glial-vascular signal transduction (Allen and Barres, 2009 ). In addition, GFAP is increased in various pathologies and thus may be used as a marker of neuronal and glial damage (Holmberg et al., 1998; Tullberg et al., 1998) .
The aim of this study was to evaluate whether mildronate exerts protective effects also in toxicity models obtained by anti-HIV drugs of other classes, such as non-nucleoside analogue reverse transcriptase inhibitors (NNRTI) and protease inhibitors (PI). We suggested that this study may broaden the spectrum of protective action of mildronate. For this purpose, we chose two anti-HIV drugs: indinavir and efavirenz, representatives of PI and NNRTI classes, respectively. In vitro studies on adipocytes showed indinavir to worsen mitochondrial function (Viengchareun et al., 2007) . Furthermore, in a myoblast cell line it caused multiple defects in translation initiation affecting protein synthesis (Hong-Brown et al., 2004) . In comparison to other reverse transcriptase inhibitors, efavirenz in a human hepatoma cell line did not cause mitochondrial toxicity (Walker et al., 2002) . However, it affected liver function (Kontorinis and Dieterich, 2003) , and in mice brain tissue inhibited creatine kinase activity, indicating central nervous system toxicity (Streck et al., 2008) .
MATERIALS AND METHODS

Chemicals. Indinavir (2S
, Crixivan* as 400 mg capsules was manufactured by Merck Sharp & Dohme Ltd (UK) and efavirenz ((4S)-6-chloro-4-(2-cyclopropylethynyl)-4-(trifluoromethyl) -2,4-dihydro-1H-3,1-benzoxazin-2-one), Sustiva* as 100 mg capsules by Bristol-Myers Squibb (UK). Mildronate [3-(2,2,2-trimethylhydrazinium) propionate dihydrate], was synthesised at the Latvian Institute of Organic Synthesis, and manufactured by the Joint Stock Company Grindex (Riga, Latvia). Mildronate was dissolved in saline and prepared as a 2% stock solution. A water suspension of indinavir and efevirenz (1% stock suspension) was made by adding 1-2 drops of 0.6% TWIN-80, and then diluted by saline to an appropriate concentration. The NF-kBp65 rabbit polyclonal antibody (AbCam, UK), dilution 1 : 200; active caspase-3 rabbit polyclonal antibody (AbCam, UK) was used in a dilution 1 : 100; and rabbit polyclonal to glial fibrillary acidic protein (GFAP) -astrocyte marker antibody (DAKO, Denmark), a dilution 1 : 500. Peroxidase conjugated polyclonal goat anti-rabbit IgG and polyclonal rabbit anti-goat IgG, serum-free protein block, citrate buffer, 0.5% H 2 O 2 and diaminobenzidine were from Dako, Denmark.
Animals. Animals (male ICR mice) were obtained from the Laboratory of Experimental Animals, Rîga Stradiòð University, Latvia, each weighing 17.0 ± 0.1 g at the beginning of experiment. The environment was maintained at a temperature of 22.0 ± 0.5 o C with a 12-h light/dark cycle. Rats were fed a standard laboratory diet.
Experiment design. The experiment was carried out in mice by daily intraperitoneal administration of both mildronate and indinavir or efavirenz for two weeks. Mildronate was used at 100 mg/kg (a dose that we previously found to be the most effective in experiments with azidothymidine (Klusa et al., 2006) ; indinavir and efavirenz at 50 mg/kg (similar azidothymidine dose was administered in previous experiments (Klusa et al., 2006) . Drugs were injected in a volume of 10 ml/kg intraperitoneally in both left and right sides of the following mice groups (eight animals per group):
Group 1 On day 15, mice were sacrificed by decapitation. Cardiac tissue, as well as liver and brain tissue for the efavirenz group were removed and fixed in 10% neutral buffered formalin, processed and embedded routinely.
Immunohistochemical examination. For immunohistochemistry, paraffin-embedded tissue was cut in 4-micronthick sections. According to the immunohistochemical method described elsewhere (Di Stefano et al., 2002) , tissue sections were stained for visualisation of NF-kBp65 positive cells (nuclear immunostaining), and caspase-3, and GFAP positive cells (cytoplasmic immunostaining). Briefly, antigen retrieval was achieved by treatment in a microwave for 20 min at 300 W in citrate buffer, pH = 6.0. Endogenous peroxidase activity was blocked by 0.5% H 2 O 2 for 10 minutes. Nonspecific primary antibody binding was blocked by serum-free protein block for 10 minutes. Rabbit polyclonal NF-kBp65 antibody was applied at 1 : 200 and incubated overnight at 4 o C. Active caspase-3 and GFAP antibodies were applied at 1 : 200 and 1 : 500, respectively, and incubated for 1 hour at room temperature. Detection of primary antibody binding was performed using specific peroxidase conjugated polyclonal goat anti-rabbit IgG (at 1 : 100 for 30 min) and subsequently peroxidase conjugated polyclonal rabbit anti-goat IgG at 1 : 100 for 30 minutes. The immunoperoxidase colour reaction was developed by incubation with diaminobenzidine (5 min). A negative control without primary antibody was included in each staining run. NF-kBp65 nuclear immunolocalisation in cardiomyocytes, inflammatory and endothelial cells, as well as caspase-3 cytoplasmic immunolocalisation in cardiomyocytes and hepatocytes, and GFAP cytoplasmic immunolocalisation in neuronal cells, respectively, were counted using image analysis software in ten high-powered fields (at magnification ×400), and their total number was recorded. All cell counts were expressed as cells per mm 2 . Slides were coded and counted by two pathologists in blinded fashion. Cardiac tissue sections were counterstained with haematoxylin eosin to allow the identification of NF-kBp65 positive cells of different lineages by their anatomic features: cell nuclear size and shape, spatial arrangement and distribution. Thus, the cardiomyocyte origin of the NF-kBp65 positive nuclear immunolocalisation was confirmed by the presence of myofilaments in the cytoplasm. Anatomically cells lying freely either in capillary lumina or interstitium were considered as infiltrating leukocytes. Only elongated cells lying along the inner walls of vessels were defined as endothelial cells. However, differentiation of different lineages of NF-kBp65 positive cells was possible in transverse but not in cross sections. Therefore, we assessed the total number of cells with NF-kBp65 nuclear staining.
According to the intensity of NF-kBp65, caspase-3 or GFAP positive staining, three types of staining patterns were mainly observed: unstained, lightly and strongly stained. For counting, only cells that showed strong staining were regarded as positive.
Morphological examination. Paraffin-embedded tissue was cut in 4-micron-thick sections and stained with haematoxylin and eosin for morphological examination.
The extent of myocardial necrosis was measured using a light microscope (Leica) coupled to an analysis system (Image ProPlus). Ten high-power fields at magnification ×400 were captured (surface area of one high-power field at magnification ×400 = 0.229 mm 2 ). The myocardial necrotic changes (early signs of coagulation necrosis) were identified by myocyte hypereosinophilia, pyknosis of nuclei, waviness of fibers at the border, interstitial oedema, no or occasional inflammatory cells in the interstitium, whereas a total coagulation necrosis was characterised by myocytes with shrunken eosinophilic cytoplasm, loss of nuclei and cross striation, accompanied by edema and inflammatory cell infiltration of the interstitium (Akasaka, 2006) . The relevant area was outlined on a captured image and the necrotic area was measured. The results were expressed as a percentage of necrotic area (represented both early changes and coagulation necrosis) to the total area examined.
Cellular infiltration in heart tissue was assessed on a scale, where 0 = no infiltration, 1 = infiltration less than 25%, 2 = infiltration between 25% and 50%, 3 = infiltration between 50% and 75%, and 4 -infiltration more than 75% of analysed myocardial field; cardiomyocyte necrotic changes were expressed in percentage of the total myocardial field.
In brain tissue, we assessed infiltration of inflammatory cells, analysed according to regions (magnification ×400): 1) subcortical perivascular, 2) subcortical parenchymal, and 3) intracortical perivascular. Perivascular infiltrates were defined as inflammatory cells, which are located not further than three cell layers from blood vessels. Inflammatory cells that were further than three layers from blood vessel wall were defined as parenchymal infiltrates. Infiltration of inflammatory cells was assessed according to a four score scale: 0 -no infiltration; 1 -light infiltration; 2 -medium infiltration; 3 -marked infiltration; 4 -very marked infiltration (more than 25% of the total field of vision).
Morphology of liver tissue was evaluated by assessing the histological activity index (HAI), according to Ishak et al. (1995) Statistics. For statistical analysis GraphPad Prism 4 software was used. Results are expressed as the mean ± SE values, and significance was set at P < 0.05 (unpaired t-test or Mann-Whitney U test for cellular infiltration scores). did not reduce this indinavir effect (4.5 ± 0.7 %). Indinavir caused also focal cardiomyocyte fatty degeneration and vacuolisation, but mildronate had no effect on this (data not shown). Figure 2 shows that indinavir increased (2-fold) cellular infiltration in mice cardiac tissue (1.9 ± 0.3 scores). Mildronate showed only a tendency to reduce this cellular infiltration (1.1 ± 0.1 vs. 1.9 ± 0.3 scores, P > 0.05). Efavirenz at dose 50 mg/kg, administered for two weeks, did not cause significant histopathological changes in mice cardiac tissue (data not shown).
RESULTS
Effect of mildronate on immunohistochemical and mor-
Effect of mildronate on immunohistochemical and morphological alterations in mice brain tissue. Efavirenz increased caspase-3 expression in mice brain tissue, in comparison to the saline control group (3.9 ± 0.4 vs. 2.4 ± 0.6 cells/mm 2 , P < 0.05, Fig. 3 ). Mildronate (100 mg/kg) per se did not change caspase-3 expression in mice brain tissue, but it decreased efavirenz-induced caspase-3 expression (2.2 ± 0.1 vs. 3.9 ± 0.4 cells/mm 2 , P < 0.05, Fig. 3 ). Efavirenz increased also glial fibrillary acidic protein (GFAP) expression, compared to the saline control group (40.0 ± 4.8 vs. 23.0 ± 5.1 cells/mm 2 , P < 0.05, Fig. 4 ). Mildronate per se did not increase GFAP expression, while in combination with efavirenz it reduced GFAP expression induced by efavirenz (25.1 ± 1.8 vs. 40.0 ± 4.8 cells/mm 2 , P < 0.01, Fig. 4) . Our results showed that efavirenz caused also small degenerative changes in mice brain tissue, which were manifested as focal neuronal and perivascular edema, and perivascular cellular infiltration. Mildronate protected brain tissue against efavirenz-induced neuronal pericellular and perivascular edema (data not shown).
Effect of mildronate on immunohistochemical and morphological alterations in mice liver tissue. Efavirenz (50 mg/kg) like saline (control) and mildronate (100 mg/kg) did not alter caspase-3 expression in mice liver tissue (data not shown). Efavirenz caused small degenerative alterations in mice liver tissue, manifested as small hepatocyte vacuolar and fatty degeneration, dilated portal tracts, infiltration of inflammatory cells, and increased number of megakaryocytes. The obtained alterations were evaluated as histological activity index (HAI) with scores: 3.1 ± 0.3 vs. 0.9 ± 0.3 in the control group, (P < 0.0001), Fig. 5 . Mildronate (100 mg/kg) per se caused small hepatocyte vacuolar and focal fatty degeneration (scores 1.8 ± 0.2 vs. 0.9 ± 0.3 of the control, P > 0.05, Fig. 5 ), while in combination with efavirenz it had a tendency to decrease the evafirenz-induced increase in HAI: 2.6 ± 0.2 vs. 3.1 ± 0.3 scores, P > 0.05, Fig. 5 .
DISCUSSION
In the present study, we examined the influence of mildronate on the toxic effects of indinavir and efavirenz, anti-HIV drugs of the PI and NNRTI classes, respectively. The morphological and immunohistochemical examination of mice tissue after a two-week administration regimen of these drugs showed that indinavir (PI) significantly affected cardiac tissue: it increased the expression of NF-kBp65, as well as induced cardiomyocyte necrosis, fatty degeneration and vacuolisation, indicating inflammatory and degenerative responses in cardiac cells. Mildronate (at a dose of 100 mg/kg) effectively reduced the overexpression of NF-kBp65, but it had no effect on cardiomyocyte necrosis, fatty degeneration and vacuolisation. Efavirenz (NNRTI) did not have a toxic effect on heart tissue, as we observed neither an increase in NF-kBp65 and caspase-3 expression, nor morphological alterations.
In the cardiotoxicity model, the tested drugs of PI and NNRTI classes showed distinct effects in comparison to those obtained previously in NRTI drug studies. Mildronate clearly protected against the action of NRTIs, such as azidothymidine, the most toxic agent among anti-HIV drugs, as well as lamivudine and stavudine, since mildronate reduced both NF-kBp65 overexpression and the histopathological changes in mice myocardium (Klusa et al., 2006; Isajevs et al., 2007) . The mechanism of NRTIs is demonstrated to be provided via mitochondria-compromising effects (Badley et al., 2003) . Hence, the successful cardioprotection known as a very important property of mildronate, can be attributed to mitochondria-targeting, since mildronate's ability to prevent mitochondrial respiratory chain functions was found by us previously (Pupure et al., 2008) .
The mitochondrial mechanism for drugs of PI and NNRTI classes was not strongly demonstrated. In our study we showed that PI and NNRTI affect mouse tissue in different ways. Firstly, mildronate protected indinavir-induced inflammation in cardiomyocytes but not morphological alterations. Secondly, efavirenz did not cause significant cardiotoxicity. Therefore, we may speculate, on the one hand, that different tissue sensitivity to anti-HIV drugs exists, and, on the other hand, suggest their different mechanisms at the cellular level. Probably, protection of indinavir-induced NF-kBp65 expression in cardiac tissue caused by mildronate may be explained rather by its anti-inflammatory activity, and less by its anti-degenerative activity. Similarly, in hepatic tissue mildronate acted mostly against inflammatory effects caused by efavirenz.
In mice brain tissue, efavirenz caused pathological changes, such as increased expression of caspase-3 and GFAP, which were effectively reduced by mildronate. Moreover, mildronate also reduced efavirenz-induced pericellular and perivascular edema and cellular infiltration. The overexpression of caspase-3 shows apoptotic processes in neurons, while that of GFAP indicates appearance of reactivity of glial astrocytes. Since mildronate successfully normalised both these pathological neuronal and glial processes caused by efavirenz, we suggest mildronate's neuroprotective effects against efavirenz neurotoxicity. In literature there is little data about the influence of efavirenz on the CNS. It was shown that efavirenz may inhibit creatine kinase activity in the brain (Streck et al., 2008) . Function of this enzyme is to catalyze the conversion of creatine to phosphocreatine by applying itself in the consumption of adenosine triphosphate, hence playing a significant role in cell energy homeostasis (Streck et al., 2008) . Recently creatine kinase together with lactate dehydrogenase, neuron specific enolase, GFAP and others has been proposed as potential markers of brain injury (Korfias et al., 2009) . The influence of mildronate on brain creatine kinase activity has not yet been shown; one may only suggest its protective influence on this enzyme.
In conclusion, the obtained data demonstrate that daily two-week intraperitoneal administration (dose of 50 mg/kg, in mice) of indinavir, a representative of PI class, showed weak cardiotoxic effects, while efavirenz, a representative of NNRTI class, lacked this toxicity. However, efavirenz showed marked alterations in mice brain tissue and weak toxic effects in liver tissue. Mildronate protected from indinavir-induced cardiotoxicity and efavirenz-induced neurotoxicity. Distinct tissue sensitivity and specificity to these drugs, on one hand, and different intensity of mildronate's ability to protect tissue against drug toxic effects, on the other hand, indicate usefulness of mildronate as a protective agent in clinical use of indinavir and/or efivarenz as anti-HIV/anti-AIDS drugs. Probably tissue-protective activity of mildronate involves not only mitochondria-regulating but also other cellular mechanisms. control group, unpaired t-test.
